Skip to search formSkip to main content

naptumomab estafenatox

A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Tumor recognition is a key factor in checkpoint inhibitors (CPI) efficacy and acquired resistance. Lack or loss of tumor antigens… Expand
Is this relevant?
2017
2017
3073 Background: Naptumomab estafenatox/ANYARA (Nap) is a fusion protein of an antibody (5T4) and a superantigen (SEA/E-120… Expand
Is this relevant?
2016
2016
PURPOSE To prospectively determine the efficacy of naptumomab estafenatox (Nap) + IFNα versus IFN in metastatic renal cell… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2014
Review
2014
Improvement of cancer therapy by introducing new concepts is still urgent even though there have been major advancements lately… Expand
  • figure 1
  • table 1
Is this relevant?
2013
2013
The T lymphocytes are the most important effector cells in immunotherapy of cancer. The conceptual objective for developing the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Antibody-targeted superantigens have a potential to become useful drugs for tumor therapy. However, clinical practice has… Expand
Is this relevant?
Review
2010
Review
2010
IMPORTANCE OF THE FIELD New agents that specifically engage the immune system are being tested in a variety of malignancies. This… Expand
Is this relevant?
2009
2009
PURPOSE Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2006
2006
3083 Background: ABR-217620 (naptumomab estafenatox) is a recombinant fusion protein that consists of the 5T4Fab moiety… Expand
Is this relevant?